Abstract:Cytotoxic chemotherapy drugs which are used for treating malignant cells cannot distinguish between normal and cancerous cells. This would lead to adverse side effects. Moreover, drug resistance is another major problem of the classical chemotherapy during the treatment period. Recently, various therapeutic strategies have been developed for cell-specific targeting of anti-neoplastic drugs. Among the various kinds of drug delivery systems, (immuno) liposome has attracted high attention for its unique features such as high loading capacity, lower toxicity, delivery of soluble/non-soluble drugs, targeting and versatile structural specifications that permit easy surface decoration. Idarubicin is a semisynthetic anticancer drug that is widely used for treatment of leukemia as well as other kinds of cancers. In this study, liposomes were covered with biocompatible polyethylene glycol (PEG) and dress up with a monoclonal antibody (mAb) Trastuzumab (Herceptin®). Trastuzumab is a humanized mAb approved by FDA for ablation of HER-2 over express cells in metastatic breast cancer. The constructed immunoliposome was loaded by Idarubicin. Shape, polarity, and size of synthesized immunoliposomes were characterized by the Atomic Force Microscopy (AFM) and Dynamic Light scattering (DLS) methods. SK-BR3 and MCF7 cell lines were used as HER2- positive and HER2-negative cells, respectively. Cell lines were treated with different concentrations of Idarubicin either in the free form or entrapped in liposomes/ immunoliposomes. After treatment, growth of malignant cells was evaluated by MTT assay. Mean diameter and zeta potential of the prepared Idarubicin-loaded anti-HER2 immunoliposomes were 160 nm and –20 mV, respectively. Cell lines responded to Idarubicin in a concentration dependent manner. According to the obtained results, Idarubicin showed potent toxic effect on both kinds of cell lines, however; SK-BR3 cells were significantly more sensitive. In comparison, Idarubicin in the form of immunoliposome was more potent in the killing of SK-BR3 malignant cells.

HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis

Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency

HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain

Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins

Fusion of apoptosis‐related protein Cytochrome c with anti‐HER‐2 single‐chain antibody targets the suppression of HER‐2+ breast cancer

Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells

Precise HER2 Protein Degradation via Peptide‐Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution

TfR-T12 short peptide and pH sensitive cell transmembrane peptide modified nano-composite micelles for glioma treatment <i>via</i> remodeling tumor microenvironment

Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A

Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity

Anti‐HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone‐Fused Enediyne

Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo

In Silico Exploration and Biological Evaluation of Bispecific Peptides Derived from Anti-HER2 Antibodies and Peptide-Camptothecin Conjugates for HER2-Positive Breast Cancer

Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines

Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16]

Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells

113: SPECIFIC TARGETING OF HER2-POSITIVE BREAST CANCER CELL LINE (SK-BR3) USING IDARUBICIN-LOADED ANTI-HER2 IMMUNOLIPOSOME